169 related articles for article (PubMed ID: 1948809)
1. [Polyethylene glycol-adenosine deaminase: a new adenosine deaminase deficiency therapy. Value of deoxyadenosine triphosphate determination for therapeutic monitoring].
Bory C; Boulieu R; Souillet G; Hershfield MS
Therapie; 1991; 46(4):323-6. PubMed ID: 1948809
[TBL] [Abstract][Full Text] [Related]
2. Comparison of red cell transfusion and polyethylene glycol-modified adenosine deaminase therapy in an adenosine deaminase-deficient child: measurement of erythrocyte deoxyadenosine triphosphate as a useful tool.
Bory C; Boulieu R; Souillet G; Chantin C; Rolland MO; Mathieu M; Hershfield M
Pediatr Res; 1990 Aug; 28(2):127-30. PubMed ID: 2395602
[TBL] [Abstract][Full Text] [Related]
3. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase.
Hershfield MS; Buckley RH; Greenberg ML; Melton AL; Schiff R; Hatem C; Kurtzberg J; Markert ML; Kobayashi RH; Kobayashi AL
N Engl J Med; 1987 Mar; 316(10):589-96. PubMed ID: 3807953
[TBL] [Abstract][Full Text] [Related]
4. A 9-yr evaluation of carrier erythrocyte encapsulated adenosine deaminase (ADA) therapy in a patient with adult-type ADA deficiency.
Bax BE; Bain MD; Fairbanks LD; Webster AD; Ind PW; Hershfield MS; Chalmers RA
Eur J Haematol; 2007 Oct; 79(4):338-48. PubMed ID: 17680812
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and functional abnormalities in lymphocytes from an adenosine deaminase-deficient patient during enzyme replacement therapy.
Hutton JJ; Wiginton DA; Coleman MS; Fuller SA; Limouze S; Lampkin BC
J Clin Invest; 1981 Aug; 68(2):413-21. PubMed ID: 7263861
[TBL] [Abstract][Full Text] [Related]
6. Effect of polyethylene glycol-modified adenosine deaminase (PEG-ADA) therapy in two ADA-deficient children: measurement of erythrocyte deoxyadenosine triphosphate as a useful tool.
Bory C; Boulieu R; Souillet G; Chantin C; Guibaud P; Hershfield MS
Adv Exp Med Biol; 1991; 309A():173-6. PubMed ID: 1789201
[No Abstract] [Full Text] [Related]
7. T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase.
Weinberg K; Hershfield MS; Bastian J; Kohn D; Sender L; Parkman R; Lenarsky C
J Clin Invest; 1993 Aug; 92(2):596-602. PubMed ID: 8349799
[TBL] [Abstract][Full Text] [Related]
8. Formation and degradation of deoxyadenosine nucleotides in inherited adenosine deaminase deficiency.
Simmonds HA; Webster DR; Perrett D; Reiter S; Levinsky RJ
Biosci Rep; 1982 May; 2(5):303-14. PubMed ID: 6980023
[TBL] [Abstract][Full Text] [Related]
9. Severe combined immunodeficiency in a child with a healthy adenosine deaminase deficient mother.
Schmalstieg FC; Mills GC; Tsuda H; Goldman AS
Pediatr Res; 1983 Dec; 17(12):935-40. PubMed ID: 6606796
[TBL] [Abstract][Full Text] [Related]
10. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years.
Hershfield MS
Clin Immunol Immunopathol; 1995 Sep; 76(3 Pt 2):S228-32. PubMed ID: 7554473
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).
Chan B; Wara D; Bastian J; Hershfield MS; Bohnsack J; Azen CG; Parkman R; Weinberg K; Kohn DB
Clin Immunol; 2005 Nov; 117(2):133-43. PubMed ID: 16112907
[TBL] [Abstract][Full Text] [Related]
12. Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency.
Cohen A; Hirschhorn R; Horowitz SD; Rubinstein A; Polmar SH; Hong R; Martin DW
Proc Natl Acad Sci U S A; 1978 Jan; 75(1):472-6. PubMed ID: 272665
[TBL] [Abstract][Full Text] [Related]
13. Overproduction of adenine deoxynucleosides and deoxynucletides in adenosine deaminase deficiency with severe combined immunodeficiency disease.
Donofrio J; Coleman MS; Hutton JJ; Daoud A; Lampkin B; Dyminski J
J Clin Invest; 1978 Oct; 62(4):884-7. PubMed ID: 308954
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of adenosine deaminase deficiency with adenosine deaminase combined with polyethylene glycol].
Girault D; Le Deist F; Debré M; Pérignon JL; Herbelin C; Griscelli C; Sciudery D; Hershfield M; Fischer A
Arch Fr Pediatr; 1992 Apr; 49(4):339-43. PubMed ID: 1497422
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of adenosine deaminase-deficient human T cell lines.
Kohn DB; Mitsuya H; Ballow M; Selegue JE; Barankiewicz J; Cohen A; Gelfand E; Anderson WF; Blaese RM
J Immunol; 1989 Jun; 142(11):3971-7. PubMed ID: 2497184
[TBL] [Abstract][Full Text] [Related]
16. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency.
Chaffee S; Mary A; Stiehm ER; Girault D; Fischer A; Hershfield MS
J Clin Invest; 1992 May; 89(5):1643-51. PubMed ID: 1569204
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of biochemical, clinical and immunological parameters in severe combined immunodeficiency due to adenosine deaminase deficiency.
Morgan G; Levinsky RJ; Hugh-Jones K; Fairbanks LD; Morris GS; Simmonds HA
Clin Exp Immunol; 1987 Dec; 70(3):491-9. PubMed ID: 3436096
[TBL] [Abstract][Full Text] [Related]
18. Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy.
Hershfield MS; Chaffee S; Sorensen RU
Pediatr Res; 1993 Jan; 33(1 Suppl):S42-7; discussion S47-8. PubMed ID: 8433874
[TBL] [Abstract][Full Text] [Related]
19. Purine metabolism in adenosine deaminase deficiency.
Simmonds HA; Sahota A; Potter CF; Perrett D; Hugh-Jones K; Watson JG
Ciba Found Symp; 1978; (68):255-62. PubMed ID: 387357
[TBL] [Abstract][Full Text] [Related]
20. Rejection of bone marrow transplant and resistance of alloantigen reactive cells to in vivo deoxyadenosine in adenosine deaminase deficiency.
Cowan MJ; Shannon KM; Wara DW; Ammann AJ
Clin Immunol Immunopathol; 1988 Nov; 49(2):242-50. PubMed ID: 2971490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
